NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting a Record Number of 15 INDs Authorized in 2017 Covering 12 Tumo...
January 05 2018 - 3:44AM
Business Wire
NantKwest (NASDAQ: NK), a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of the human immune system using natural killer (NK)
cells to treat cancer, announced today that the company will be
hosting an Investor/Analyst Day on Tuesday, January 9th in San
Francisco, California.
NantKwest will be sharing with analysts and investors a review
of the company’s activities in 2017 and provide a detailed overview
for 2018. The record number of 15 INDs authorized in 2017 (aNK,
haNK, Cryopreserved haNK and taNK) will be announced, detailing the
multiple tumor types to be studied with combination chemo-radiation
therapy and activators of adaptive immune system through
adenovirus, yeast and super agonist IL-15 platforms. In addition,
details will be presented regarding authorization in Europe to
treat patients with glioblastoma and authorization by the FDA to
initiate high-affinity natural killer (haNK) cell trials in cancer
patients with HIV.
First in-human clinical data will be revealed including safety
and early signs of clinical activity in patients receiving freshly
cultured haNK, cryopreserved haNK and combinations of NK cells (aNK
and haNK) with adenovirus, yeast, and super agonist IL-15
platforms. These studies form the basis for multiple Phase II and
registration trials anticipated to be initiated in 2018.
At this event, senior management of NantKwest will provide a
review of its ongoing R&D program, as well as provide an
in-depth clinical trial roadmap for the company’s clinical programs
for 2018 and the current status of the GMP manufacturing
plants.
A webcast of the event will begin at 7:00 PM PT on Tuesday,
January 9, 2018 and is expected to conclude at 9:00 PT. A link to
the live webcast can be accessed by visiting the Investors page of
the company’s website. In addition, a replay of the event will be
posted on the website after the event and will be available for 30
days following the event.
About NantKwest
NantKwest (Nasdaq:NK) is a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of our immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases. NK
cells are the body’s first line of defense due to the innate
ability of NK cells to rapidly identify and destroy cells under
stress, such as cancer or virally-infected cells.
NantKwest’s unique NK cell-based platform, with the capacity to
grow active killer cells as a biological cancer therapy, has been
designed to induce cell death against cancer or infected cells by
three different modes of action: (1) Direct killing using activated
NK cells (aNK) that release toxic granules directly into the cell
through cell to cell contact, (2) Antibody-mediated killing using
haNKs, which are NK cells engineered to incorporate a high affinity
receptor that binds to an administered antibody, enhancing the
cancer cell killing effect of that antibody, and (3) Targeted
activated killing using taNKs, which are NK cells engineered to
incorporate chimeric antigen receptors (CARs) to target
tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of
T cell therapies including the reduction of risk of serious
“cytokine storms” reported after T cell therapy. As an
“off-the-shelf” therapy, NantKwest’s NK cells do not rely on a
patient’s own often compromised immune system. In Phase 1 clinical
trials in patients with late stage cancer, NantKwest’s NK cells
have been successfully administered as an outpatient infusion
therapy without any reported severe side effects, even at doses of
10 billion cells.
By leveraging an integrated and extensive genomics and
transcriptomics discovery and development engine, together with a
pipeline of multiple, clinical-stage, immuno-oncology programs that
include a Phase 2 trial for a rare form of melanoma and the planned
initiation of a clinical trial of NK cells targeted to breast
cancer, we believe NantKwest is uniquely positioned to be the
premier immunotherapy company and transform medicine by delivering
living drugs in a bag and bringing novel NK cell-based therapies to
routine clinical care. For more information, please visit
www.nantkwest.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180105005252/en/
NantKwestInvestor Contact:David PyrceSVP, Innovation and
Investor RelationsCell,
951-551-0949david.pyrce@nantkwest.comorMedia Contact:Jen
HodsonPublic Relations DirectorCell,
562-397-3639jhodson@nantworks.com
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Apr 2023 to Apr 2024